Ichnos Glenmark Innovation’s Post

Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update. Pharmaceuticals (Basel). 2023 Apr 6;16(4):550. doi: 10.3390/ph16040550. PMID: 37111307; PMCID: PMC10142093.

1. 🧬 Capricor Therapeutics, Inc. receives FDA update for its Duchenne muscular dystrophy program. 2. ✨ Tonix Pharmaceuticals progresses TNX-102 SL therapy for fibromyalgia treatment. 3. ✅ FDA clears Innate Pharma's Phase 1 study for IPH4502 in immune therapy. 4. 🎗️ AstraZeneca and Daiichi Sankyo US Sankyo’s drug shows positive results in breast cancer trials. Know complete story- https://lnkd.in/dKhZfHxi #Capricor #DMD #FDAUpdate #Fibromyalgia #Tonix #TNX102SL #InnatePharma #ClinicalTrials #BreastCancer #DatopotamabDeruxtecan #AstraZeneca #DaiichiSankyo #Healthcare #Pharma #Biotech

🚨 A new targeted drug combination treatment, described as a ‘step-change in care’ for #cancer patients, has today been recommended by NICE - National Institute for Health and Care Excellence. ✅ Dabrafenib, marketed as Finlee, in combination with trametinib, which is sold as Spexotras, (both made by Novartis) is being recommended in final draft guidance for treating BRAF V600E mutation-positive glioma. 📈 Clinical trials show the new treatment stalls the tumour growth in people for an average of more than two years – three times longer than current drugs. 🗣️ Read on to find out NHS England perspective 👉  https://lnkd.in/ePuUJAh3 #pharma #lifesciences #braincancer #clinicaltrial

Reflecting on an enriching experience at the "Current Drug Research Topics in Pharmacy" online symposium! 🌟 I had the pleasure of attending the thought-provoking online symposium entitled "Current Drug Research Topics in Pharmacy: An Overview of Novelties in Cancer Treatment," which took place on February 15, 2024, under the esteemed supervision of Prof. Esra TATAR, Vice Editor of the Journal of Research in Pharmacy an international open-access journal of pharmacy and pharmaceutical sciences Marmara University The symposium delved into cutting-edge research and advancements in cancer treatment, covering a wide range of topics presented by esteemed speakers #cancer #cancerresearch #drugdiscovery #pharmacy #symposium#jrp

NEWS Valutazione clinica dei #radiofarmaci terapeutici in #oncologia - Linee guida scientifiche 07 October 2024 EMA/CHMP/451705/2024 2 Committee for Medicinal Products for Human Use (CHMP) Concept paper on clinical evaluation of therapeutic 4 radiopharmaceuticals in Oncology

Interested in key takeaways from #ESMO? FirstWord Pharma's editor-in-chief of pharmaceutical news analysis, Simon King, highlights long-term use of immunotherapy and its increasingly important role in some early-stage cancers as being among the key themes from this year's European Society for Medical Oncology (ESMO) congress.  Link to full story and daily coverage from ESMO => https://lnkd.in/dhmRMSY5 #patientcases #pharma #righttreatmenttorightpatientatrighttime

Insightful webinar by Association Française de Pharmacologie Translationnelle (AFPT) on 23 September 2024! Dose optimization in oncology drug development is at the heart of the recent US FDA’s project Optimus initiative, to better satisfy the benefit:risk ratio for the patients as early as possible. A new paradigm is emerging. Join this webinar with 2 expert speakers, Gu Mi , Ph D (Biostatistics) and laurent nguyen, Pharm D, Ph D (Clinical PK and pharmacometrics), involved in oncology drug development.

The publication of our manuscript, "Efficacy and Safety of Treatments Used in Differentiated Thyroid Cancer (DTC): A Systematic Review " Patients diagnosed with differentiated thyroid cancer (DTC) are offered multiple targeted therapeutics, but it is unclear which pharmaceutical therapies are most effective and safe. A systematic literature review (SLR) was performed to assess the clinical efficacy and safety of targeted therapeutics in DTC patients. A comprehensive search was performed across MEDLINE®, Embase®, and Evidence-based Medicine (EBM) Reviews databases, along with a grey literature search. Read the full analysis and insights here: 👉 https://lnkd.in/dt_4USRh 👈 Reminder: Formerly SRS HEOR is now Amethys Insights #thyroidcancer #differentiatedthyroidcancer #cancerresearch #targetedtherapies #cancertreatment #medicalresearch #pharma #systematicreview #clinicaltrials #cancercare #healthcare

Longitude portfolio company Quanta Therapeutics recently announced two exciting clinical trial updates from its pipeline of KRAS-directed drug candidates: - The first patient has been dosed in the monotherapy portion of a Phase 1 clinical trial evaluating QTX3046, a KRASG12D-selective inhibitor. - Patient dosing has begun in the combination portion of the ongoing Phase 1 clinical trial assessing QTX3034, G12D-preferring multi-KRAS inhibitor, and cetuximab. The company focuses on developing innovative, oral therapeutics for RAS-driven cancers, and both clinical trials are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more about the clinical trials here: https://lnkd.in/eRHZAqCZ #biotech #clinicaltrials #cancerresearch

𝐔𝐫𝐨𝐆𝐞𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐅𝐃𝐀 𝐀𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐍𝐃𝐀 𝐟𝐨𝐫 𝐔𝐆𝐍-𝟏𝟎𝟐 UroGen Pharma (Nasdaq: URGN) UroGen Pharma announced that the FDA has accepted the New Drug Application (NDA) for UGN-102 (mitomycin) intravesical solution. If approved, UGN-102 could become the first FDA-approved treatment for low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA set a PDUFA goal date of June 13, 2025. “We’re thrilled about this pivotal milestone,” said Liz Barrett Liz Barrett, CEO of UroGen. “UGN-102 offers a novel approach that could meet unmet needs for patients.” Chief Medical Officer Dr. Mark Schoenberg added, “The NDA is supported by strong data, including a 79.6% complete response rate at 3 months and an 82.3% 12-month duration of response in the ENVISION trial. If approved, UGN-102 could deliver lasting results and reduce recurrence rates, representing a significant advancement for LG-IR-NMIBC management.” #FDA #Biotech #BladderCancer #CancerTreatment #UGN102 #Pharma #HealthcareInnovation